Kostas Biliouris
Stock Analyst at BMO Capital
(0.69)
# 3,745
Out of 4,827 analysts
54
Total ratings
21.74%
Success rate
-21.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $32.28 | +123.05% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $11.84 | +322.48% | 1 | Mar 12, 2025 | |
| RCKT Rocket Pharmaceuticals | Initiates: Outperform | $50 | $7.84 | +538.16% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $3.89 | +542.67% | 2 | Mar 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Market Perform | $60 → $45 | $33.61 | +33.89% | 2 | Feb 20, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $8.45 | +492.07% | 6 | Jan 10, 2025 | |
| DTIL Precision BioSciences | Upgrades: Outperform | $34 | $5.67 | +499.65% | 3 | Jan 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $20 → $35 | $13.59 | +157.64% | 6 | Sep 16, 2024 | |
| MGX Metagenomi | Maintains: Outperform | $22 → $17 | $1.57 | +986.26% | 2 | Aug 15, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $63 → $40 | $3.57 | +1,020.45% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $33.40 | +169.46% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $234 | $273.55 | -14.46% | 4 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $200 | $63.66 | +214.17% | 4 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $17.67 | +579.12% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $19.82 | +187.59% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $38.14 | -2.99% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $62.06 | +61.13% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $1.57 | +1,114.06% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $62 | $5.16 | +1,101.55% | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $37.62 | +160.50% | 1 | Jun 17, 2022 | |
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $32.28
Upside: +123.05%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $11.84
Upside: +322.48%
Rocket Pharmaceuticals
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $7.84
Upside: +538.16%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $3.89
Upside: +542.67%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Market Perform
Price Target: $60 → $45
Current: $33.61
Upside: +33.89%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $8.45
Upside: +492.07%
Precision BioSciences
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $5.67
Upside: +499.65%
Centessa Pharmaceuticals
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $13.59
Upside: +157.64%
Metagenomi
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.57
Upside: +986.26%
4D Molecular Therapeutics
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $3.57
Upside: +1,020.45%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $33.40
Upside: +169.46%
Jun 24, 2024
Maintains: Outperform
Price Target: $234
Current: $273.55
Upside: -14.46%
Jun 24, 2024
Maintains: Outperform
Price Target: $170 → $200
Current: $63.66
Upside: +214.17%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $17.67
Upside: +579.12%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $19.82
Upside: +187.59%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $38.14
Upside: -2.99%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $62.06
Upside: +61.13%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $1.57
Upside: +1,114.06%
Jul 18, 2022
Maintains: Outperform
Price Target: $48 → $62
Current: $5.16
Upside: +1,101.55%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $37.62
Upside: +160.50%